GSTM1 null genotype underpins recurrence of NF2 meningiomas
The <i>GSTM1</i> null genotype is a novel biomarker of 1p<sup>-</sup>22q<sup>-</sup>NF2<sup>-</sup> meningioma recurrence that resolves heterogeneity in existing meningioma subtypes and may be used to guide future clinical management decisions on extent of treatment to improve patient outcomes.
Authors
- Tressie M. Stephens
- Jeffrey Zuccato (ORCID: https://orcid.org/0000-0001-5418-8238)
- Anthony C. Johnson (ORCID: https://orcid.org/0000-0002-0939-6027)
- Alla V. Tsytsykova (ORCID: https://orcid.org/0000-0003-4242-9828)
- Pamela S. Jones (ORCID: https://orcid.org/0000-0002-4573-3641)
- Khanh P. Phan
- Erdyni N. Tsitsikov
- Christopher S. Graffeo (ORCID: https://orcid.org/0000-0001-5314-1067)
- Sanaa Hameed
- Gavin P. Dunn (ORCID: https://orcid.org/0000-0001-9302-4834)
- Andrew M. Bauer (ORCID: https://orcid.org/0000-0001-9458-6951)
- Yufeng Liu (ORCID: https://orcid.org/0000-0002-8118-4336)
- Ian F. Dunn (ORCID: https://orcid.org/0000-0003-0275-6736)
Institutions
- Harvard University (US)
- Massachusetts General Hospital (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-12-12
- DOI
- https://doi.org/10.3389/fonc.2024.1506708
- Citations
- 1
- Primary Topic
- Meningioma and schwannoma management
- Type
- article
- Field-Weighted Citation Impact
- 0.39